BMS has set a list price of $6,164 for a 30-day supply of the new drug, which is around 42% higher than the $4,344 Amgen charges wholesalers for a 30-day supply of Otezla, ...

PRX005 originally arose from a 2018 alliance between Prothena and Celgene, which was acquired by BMS in 2019, and also covers two other proteins thought to be involved in Alzheimer’s pathology.